Last reviewed 2026-04-23 · How we verify

Neonatal Morphine Solution

Morphine is a potent opioid agonist that binds to opioid receptors in the brain and spinal cord, producing analgesia and sedation.

Morphine is a potent opioid agonist that binds to opioid receptors in the brain and spinal cord, producing analgesia and sedation. Used for Neonatal abstinence syndrome.

At a glance

Mechanism of action

Morphine works by activating mu-opioid receptors, which are responsible for pain perception and modulation. This activation leads to a decrease in the transmission of pain signals to the brain, resulting in analgesia. Additionally, morphine can cause sedation and respiratory depression due to its effects on other opioid receptors.

Approved indications

• Neonatal abstinence syndrome

Common side effects

• Respiratory depression
• Nausea and vomiting
• Constipation

Key clinical trials

• Effect of Three Different Postcesarean Analgesic Techniques on QbsQor-10 Score (NA)
• Postoperative Pain Control & Relief in Neonates (PHASE4)
• Clonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome (PHASE4)
• Methadone Pharmacokinetics and Cardiac Effects in Newborns (PHASE1)
• Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome (PHASE3)
• Improving Outcomes in Neonatal Abstinence Syndrome (PHASE3)
• Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS) (PHASE2)
• The Use of Methadone in Newborn Infants (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Neonatal Morphine Solution CI brief — competitive landscape report
• Neonatal Morphine Solution updates RSS · CI watch RSS
• Tufts Medical Center portfolio CI